The rate of cutaneous squamous-cell carcinoma was lower in the dabrafenib-trametinib group than in the dabrafenib-only group ( @ % vs. @ % ) , whereas pyrexia occurred in more patients ( @ % vs. @ % ) and was more often severe ( grade @ , @ % vs. @ % ) in the dabrafenib-trametinib group .